Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention
Authors:
- Patrick T. O'GAraPOPatrick T. O'GAra
- Steven R. MesseSMSteven R. Messe
- E. Murat TuzcuETE. Murat Tuzcu
- Gloria CathaGCGloria Catha
- John C. RingJRJohn C. Ring
- 26 May 2009
- journal article
- practice guideline
- Published by Wolters Kluwer Health in Circulation
- Vol. 119 (20) , 2743-2747
Abstract
The optimal therapy for prevention of recurrent stroke or transient ischemic attack in patients with cryptogenic stroke and patent foramen ovale has not been defined. Although numerous observational studies have suggested a strong association between patent foramen ovale and cryptogenic stroke, a causal relationship has not been convincingly established for the majority of affected patients. Treatment choices include medical therapy with antiplatelet agents or vitamin K antagonists, percutaneous device closure, or open surgical repair. Whereas suture closure of an incidental patent foramen ovale is performed routinely during the course of an operation undertaken for another indication, primary surgical repair is rarely advocated in the current era. The choice between medical therapy and percutaneous device closure has been the subject of intense debate over the past several years, albeit one that has not been adequately informed by randomized, prospective clinical trial data to permit an objective comparison of the relative safety and efficacy of these respective approaches. Enrollment in clinical trials has lagged considerably despite frequent calls for participation from the US Food and Drug Administration and major professional societies. Completion and peer review of ongoing trials are critical steps to establish an evidence base from which clinicians can make informed decisions regarding the best therapy for individual patients. The present advisory strongly encourages all clinicians involved in the care of appropriate patients with cryptogenic stroke and patent foramen ovale—cardiologists, neurologists, internists, radiologists, and surgeons—to consider referral for enrollment in these landmark trials to expedite their completion and help resolve the uncertainty regarding optimal care for this condition.Keywords
This publication has 28 references indexed in Scilit:
- European PerspectivesCirculation, 2008
- Primary Prevention of Ischemic StrokeStroke, 2006
- Patent Foramen Ovale: Innocent or Guilty?JACC, 2006
- Closure of patent foramen ovale: is the case really closed as well?: Table 1Heart, 2005
- Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients With Patent Foramen OvaleStroke, 2004
- Effect of Medical Treatment in Stroke Patients With Patent Foramen OvaleCirculation, 2002
- Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale, Atrial Septal Aneurysm, or BothNew England Journal of Medicine, 2001
- Paradoxical Embolism — Thrombus in Transit through a Patent Foramen OvaleNew England Journal of Medicine, 1997
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Incidence and Size of Patent Foramen Ovale During the First 10 Decades of Life: An Autopsy Study of 965 Normal HeartsMayo Clinic Proceedings, 1984